IRM Input Cache Data


 
    ESG Commitment  
 
    Technology Platforms  
 
    Clinical Trials  
 
    SOF-VAC™ - Improving mRNA Vaccines  
 
    Noxopharm Overview - Chinese  
 
    Appendix 4D and Half Year 2024 Financial Report  
 
    Appendix 4D and Half Year 2024 Financial Report  
 
    Appendix 4D and Half Year 2024 Financial Report  
 
    Investor Fact Sheet  
 
    Noxopharm extends Hudson Institute strategic partnership  
 
    Noxopharm extends Hudson Institute strategic partnership  
 
    Corporate Governance  
 
    Corporate Governance  
 
    Corporate Governance  
 
    Whisteblower Policy (DO NOT USE)  
 
    December 2023 Quarterly Activities Report and Appendix 4C  
 
    December 2023 Quarterly Activities Report and Appendix 4C  
 
    December 2023 Quarterly Activities Report and Appendix 4C  
 
    Change of Director's Interest Notice - GM  
 
    Change of Director's Interest Notice - GM  
 
    Notification of cessation of securities - NOX  
 
    Notification of cessation of securities - NOX  
 
    About Noxopharm  
 
    Autoimmune Disease  
 
    Noxopharm SOF-SKN Fact Sheet  
 
    Sofra™  
 
    Results of Meeting  
 
    Results of Meeting  
 
    Noxopharm Enhances Cash Position via R&D Rebate  
 
    Noxopharm Enhances Cash Position via R&D Rebate  
 
    Noxopharm 2023 AGM Corporate Presentation  
 
    Noxopharm 2023 AGM Corporate Presentation  
 
    Noxopharm 2023 AGM Corporate Presentation  
 
    Noxopharm 2023 AGM Chair Address  
 
    Noxopharm 2023 AGM Chair Address  
 
    Sofra Autoimmunity and Inflammation Fact Sheet  

Sofra SOF-XX autoimmune disease and inflammation fact sheet October 2023

 
    Sofra SOF-VAC Fact Sheet  

Sofra SOF-VAC mRNA vaccine enhancer fact sheet 2023

 
    Chroma™  
 
    Chroma Pancreatic Cancer Fact Sheet  

Chroma Pancreatic Cancer Fact Sheet Oct 2023

 
    Unlisted Options Expiring on 16 December 2023  
 
    Unlisted Options Expiring on 16 December 2023  
 
    IONIC  
 
    Veyonda ®  
 
    mRNA Vaccine Enhancer Shows Inflammation Reduction  
 
    mRNA Vaccine Enhancer Shows Inflammation Reduction  
 
    Noxopharm talks partnership with Hudson Institute of Medical Research  
 
    Noxopharm talks partnership with Hudson Institute of Medical Research  
 
    September 2023 Activities Report and Appendix 4C  
 
    September 2023 Activities Report and Appendix 4C  
 
    September 2023 Activities Report and Appendix 4C  
 
    Response to ASX Query  
 
    Response to ASX Query  
 
    US FDA grants Orphan Drug Designation for CRO-67  
 
    US FDA grants Orphan Drug Designation for CRO-67  
 
    Trading Halt  
 
    Trading Halt  
 
    Pause in Trading  
 
    Pause in Trading  
 
    Latest CRO-67 data shows success in reducing cancer growth  
 
    Latest CRO-67 data shows success in reducing cancer growth  
 
    2023 AGM Notice of Meeting and Proxy  
 
    2023 AGM Notice of Meeting and Proxy  
 
    2023 AGM Letter to Shareholders and Proxy  
 
    2023 AGM Letter to Shareholders and Proxy  
 
    Noxopharm 2023 Annual Report  
 
    Annual Report to shareholders  
 
    Annual Report to shareholders  
 
    Annual Report to shareholders  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Notification of cessation of securities - NOX  
 
    Notification of cessation of securities - NOX  
 
    June 2023 Activities Report and Appendix 4C  
 
    June 2023 Activities Report and Appendix 4C  
 
    June 2023 Activities Report and Appendix 4C  
 
    Upcoming Expiry of Listed Options (ASX Code NOXOA)  
 
    Upcoming Expiry of Listed Options (ASX Code NOXOA)  
 
    Unlisted Options expiring on 23 July 2023  
 
    Unlisted Options expiring on 23 July 2023  
 
    Notification of cessation of securities - NOX  
 
    Notification of cessation of securities - NOX  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    About Pharmorage  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - BP  
 
    Change of Director's Interest Notice - BP  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - PM  
 
    Details of Company Address  
 
    Details of Company Address  
 
    Noxopharm CRO-67 Fact Sheet 2023  

Noxopharm CRO-67 Fact Sheet 2023

 
    Noxopharm - Optimising RNA Vaccines and Therapeutics  

Noxopharm - Optimising RNA Vaccines and Therapeutics

 
    Noxopharm - Novel Dual-Cell Therapy for Pancreatic Cancer  

Noxopharm - Novel Dual-Cell Therapy for Pancreatic Cancer

 
    Noxopharm - New Therapeutics for Autoimmune and Inflammatory Diseases  

Noxopharm - New Therapeutics for Autoimmune and Inflammatory Diseases

 
    Noxopharm hails new Sofra™ drug inflammation results  
 
    Noxopharm hails new Sofra™ drug inflammation results  
 
    NOXCOVID  
 
    LuPIN  
 
    Shareholder Information  
 
    The Noxopharm Network  
 
    CEO's Message  
 
    Constitution  
 
    Noxopharm Public Company Constitution  
 
    Contact Us  
 
    CEP  
 
    DARRT  
 
    A phase I/II trial of NOX66 in combination with nivolumab in patients with advanced cancer  
 
    IONIC Trial Abstract Published at ASCO  
 
    IONIC Trial Abstract Published at ASCO  
 
    Study results show new Sofra drug reduces inflammation  
 
    Study results show new Sofra drug reduces inflammation  
 
    Innovative Sofra research presented at European event  
 
    Innovative Sofra research presented at European event  
 
    Partnering  
 
    Working at Noxopharm  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Upcoming Expiry of Listed Options (ASX Code NOXO)  
 
    Upcoming Expiry of Listed Options (ASX Code NOXO)  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    March 2023 Quarterly Activities Report and Appendix 4C  
 
    March 2023 Quarterly Activities Report and Appendix 4C  
 
    March 2023 Quarterly Activities Report and Appendix 4C  
 
    Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs  
 
    Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs  
 
    Noxopharm Announces Novel mRNA Vaccine Enhancer  
 
    Noxopharm Announces Novel mRNA Vaccine Enhancer  
 
    Why Invest in Noxopharm  
 
    Investor Welcome  
 
    Appendix 4D and Half Year 2023 Financial Report  
 
    Appendix 4D and Half Year 2023 Financial Report  
 
    Appendix 4D and Half Year 2023 Financial Report  
 
    Noxopharm to Present Sofra Study at LUPUS 2023 Conference  
 
    Noxopharm to Present Sofra Study at LUPUS 2023 Conference  
 
    FY23 Corporate Governance Statement and Appendix 4G  
 
    FY23 Board Skills Matrix Summary  
 
    Anti-Bribery and Corruption Policy  
 
    Whistleblower Policy  
 
    Securities Trading Policy  
 
    Risk Management Policy  
 
    Remuneration and Nomination Committee Charter  
 
    Diversity and Inclusion Policy  
 
    Communication and Disclosure Policy  
 
    Code of Conduct  
 
    Board Charter  
 
    Audit and Risk Committee Charter  
 
    Ongoing Trials  
 
    Veyonda White Paper  
 
    December 2022 Quarterly Activities Report and Appendix 4C  
 
    December 2022 Quarterly Activities Report and Appendix 4C  
 
    December 2022 Quarterly Activities Report and Appendix 4C  
 
    DARRT-2 Trial Efficacy Phase to Commence  
 
    DARRT-2 Trial Efficacy Phase to Commence  
 
    NOX Pipeline Boosted by $1.5M Grant to Hudson Institute  
 
    NOX Pipeline Boosted by $1.5M Grant to Hudson Institute  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - FB  
 
    Notification of cessation of securities - NOX  
 
    Notification of cessation of securities - NOX  
 
    Communication and Disclosure Policy  
 
    Federal Innovation Connections Grant Awarded  
 
    Federal Innovation Connections Grant Awarded  
 
    IONIC Trial Progresses as Veyonda Passes Safety Milestone  
 
    IONIC Trial Progresses as Veyonda Passes Safety Milestone  
 
    Notification of cessation of securities - NOX  
 
    Notification of cessation of securities - NOX  
 
    Constitution  
 
    Constitution  
 
    Results of Meeting  
 
    Results of Meeting  
 
    Noxopharm 2022 AGM Corporate Presentation  
 
    Noxopharm 2022 AGM Corporate Presentation  
 
    Noxopharm 2022 AGM Corporate Presentation  
 
    Noxopharm AGM 2022 Chair's Address  
 
    Noxopharm AGM 2022 Chair's Address  
 
    CEP-2 Safety Milestone Shows Veyonda Progress  
 
    CEP-2 Safety Milestone Shows Veyonda Progress  
 
    CRO-67 is a Novel Therapeutic for Pancreatic Cancer: Implications for Tumour and Stromal Reprogramming  
 
    Noxopharm Enhances Cash Position via R&D Rebate  
 
    Noxopharm Enhances Cash Position via R&D Rebate  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    September 2022 Quarterly Activities Report and Appendix 4C  
 
    September 2022 Quarterly Activities Report and Appendix 4C  
 
    September 2022 Quarterly Activities Report and Appendix 4C  
 
    2022 AGM Notice of Meeting and Proxy  
 
    2022 AGM Notice of Meeting and Proxy  
 
    2022 AGM Letter to Shareholders and Proxy  
 
    2022 AGM Letter to Shareholders and Proxy  
 
    Unlisted Options Expiring on 21 November 2022  
 
    Unlisted Options Expiring on 21 November 2022  
 
    Ausbiz interview regarding pancreatic cancer research  
 
    Noxopharm, UNSW breakthrough promising for cancer patients  
 
    Noxopharm 2022 Annual Report  
 
    Noxopharm 2022 Annual Report  
 
    Noxopharm 2022 Annual Report  
 
    Final Director's Interest Notice - GK  
 
    Final Director's Interest Notice - GK  
 
    Resignation of Dr Graham Kelly as Non-Executive Director  
 
    Resignation of Dr Graham Kelly as Non-Executive Director  
 
    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
 
    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
 
    Novel Dual-cell Therapy Results in Pancreatic Cancer  
 
    Novel Dual-cell Therapy Results in Pancreatic Cancer  
 
    Response to ASX Price Query (Correction to ASX Ticker)  
 
    Response to ASX Price Query (Correction to ASX Ticker)  
 
    Response to ASX Price Query  
 
    Response to ASX Price Query  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Noxopharm & UNSW Pancreatic Cancer Research at US Conference  
 
    Noxopharm & UNSW Pancreatic Cancer Research at US Conference  
 
    CEP-2 Trial Passes Safety Milestone  
 
    DARRT-2 Trial Safety Milestone and European Site Activated  
 
    June 2022 Quarterly Activities Report and Appendix 4C  
 
    June 2022 Quarterly Activities Report and Appendix 4C  
 
    June 2022 Quarterly Activities Report and Appendix 4C  
 
    Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial  
 
    A$1.45M Grant to Hudson Institute for Collaboration with Noxopharm  

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

Read More

 
    $1.45M Grant to Hudson Institute for Noxopharm Collaboration  
 
    Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant  
 
    Noxopharm New Corporate Presentation June 2022  
 
    Noxopharm Corporate Presentation  
 
    Noxopharm Corporate Presentation  
 
    Noxopharm Webinar  
 
    Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.  

Read More here.

 
    Veyonda Abstract Published at ASCO Annual Meeting 2022  
 
    Noxopharm collaborators Hudson Institute of Medical Research confirm the relevance of TLR7 activation in Lupus  
 
    March 2022 Quarterly Activities Report and Appendix 4C  
 
    March 2022 Quarterly Activities Report and Appendix 4C  
 
    March 2022 Quarterly Activities Report and Appendix 4C  
 
    Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors  

Read More here.

 
    Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA  
 
    The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.  

177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

 
    Noxopharm cancer drug secures Orphan Drug Designation from FDA  

Digital pharma industry news site, Outsourcing-Pharma, spoke with Noxopharm CEO and Managing-Director, Dr Gisela Mautner about Veyonda®’s recent Orphan Drug Designation as a treatment for soft-tissue sarcoma.

Read More

 
    US FDA grants new orphan designation to Noxopharm's Veyonda  

Australian biotech news site, Biotech Dispatch reported: US FDA grants new orphan designation to Noxopharm's Veyonda - Biotech

Read More

 
    Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA  
 
    Orphan Drug Designation Granted to Noxopharm by US FDA  
 
    Orphan Drug Designation Granted to Noxopharm by US FDA  
 
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles  

Digital news site, Yahoo! Posted the following: Sarcoma trial cancer treatment begins at City of Hope in Los Angeles.

Read More

 
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles  

Global business digital news site, Bloomberg, published the announcement regarding the commencement of Noxopharm’s new sarcoma trial.

Read More

 
    Noxopharm’s CEP2 trial initiation  

US clinical trial news site, Bioworld’s ‘In the Clinic for March 8-14 2022’ noted Noxopharm’s CEP2 trial initiation.

Read More

 
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles  

Pharmaceutical news and industry site, Pharmiweb, provided this update on Noxopharm’s new sarcoma trial underway in the US.

Read More

 
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles  

Life Sciences industry digital hub, BioSpace, reported “Sarcoma Trial for New Cancer Treatment Begins at City Of Hope (Hospital) in Los Angeles.

Read More

 
    Noxopharm Ltd partner, California’s City of Hope Cancer Center, enrols and doses first patient in trial studying soft tissue sarcoma  

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.
Read More

 
    First Patient Treated in CEP-2 Sarcoma Trial  
 
    First Patient Treated in CEP-2 Sarcoma Trial  
 
    Noxopharm Ltd's half-year results include strong cash position and exclusive mRNA licensing agreement  

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.
Read More

 
    Appendix 4D and Half Year 2022 Financial Report  
 
    Appendix 4D and Half Year 2022 Financial Report  
 
    Appendix 4D and Half Year 2022 Financial Report  
 
    Health Industry Hub speaks with Noxopharm’s new CEO, Dr Mautner  
 
    Initial Director's Interest Notice - GM  
 
    December 2021 Quarterly Activities Report and Appendix 4C  
 
    December 2021 Quarterly Activities Report and Appendix 4C  
 
    December 2021 Quarterly Activities Report and Appendix 4C  
 
    Noxopharm Presents at HC Wainright BioConnect Conference 10-13 January 2022  
 
    Noxopharm Presents at H.C. Wainwright BioConnect Conference  
 
    Noxopharm Receives A$5.865M R & D Tax Rebate  
 
    Noxopharm Receives A$5.865M R & D Tax Rebate  
 
    Videos  
 
    Noxopharm Ltd appoints new CEO to lead it through next stage of development  

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.
Read More

 
    Noxopharm Announces Leadership Transition  
 
    Noxopharm Announces Leadership Transition  
 
    Noxopharm CEO Discusses the Subsidiary Pharmorage  
 
    Noxopharm Discusses the Subsidiary Pharmorage  
 
    Noxopharm DARRT-2 Cancer Trial Update  
 
    Noxopharm DARRT-2 Cancer Trial Update  
 
    The Noxopharm Newsletter Summer 2021-22  
 
    Notification of cessation of securities - NOX  
 
    Change of Director's Interest Notice - GK  
 
    December 2021- The CEO Magazine (page 122)  

Graham Kelly, CEO and Managing Director of Noxopharm, is passionate about mentoring young scientists.

Read More

 
    Noxopharm Annual General Meeting Results  
 
    Licencing Deal Expands Noxopharm Drug Opportunities  
 
    Licencing Deal Expands Noxopharm Drug Opportunities  
 
    Noxopharm 2021 AGM Corporate Presentation  
 
    Noxopharm 2021 AGM Corporate Presentation  
 
    Noxopharm 2021 AGM Corporate Presentation  
 
    Noxopharm 2021 AGM Chairmans Address  
 
    Retraction of Grant Announcement  
 
    Retraction of Grant Announcement  
 
    Trading Halt  
 
    Trading Halt  
 
    Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial  
 
    Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial  
 
    Noxopharm Podcast 1 – The Story of Noxopharm  
 
    DARRT-2 Trial Commences in the U.S.  
 
    Unlisted Options Expiring on 30 November 2021  
 
    Veyonda and Opdivo IONIC Study First Patient Dosed  
 
    Veyonda and Opdivo IONIC Study First Patient Dosed  
 
    Patent Granted for Veyonda and Low Dose Chemotherapy  
 
    Patent Granted for Veyonda and Low Dose Chemotherapy  
 
    Jobkeeper s323DB Notice  
 
    2021 AGM Notice of Meeting and Proxy  
 
    2021 AGM Letter to Shareholders and Proxy  
 
    September 2021 Quarterly Activities Report and Appendix 4C  
 
    September 2021 Quarterly Activities Report and Appendix 4C  
 
    Cleansing Notice  
 
    Application for quotation of securities - NOX  
 
    BiotechDispatch reported,US patent office allows claims for use of Noxopharm's Veyonda  

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy, including external beam radiotherapy (EBRT), with the purpose of generating abscopal responses in patients with metastatic prostate cancer.

Read more here

 
    Proactive reported, Noxopharm buoyed as US Patent Office allows abscopal response claims for Veyonda®  

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

Read here

 
    Veyonda Achieves Important U.S. Patent Claims  
 
    Veyonda Achieves Important U.S. Patent Claims  
 
    Noxopharm 2021 Annual Report  
 
    Noxopharm 2021 Annual Report  
 
    Noxopharm 2021 Annual Report  
 
    Drug Discovery World, a multi-platform global site for the drug discovery world, posted Oncology treatment tested in patients with moderate Covid-19 disease.  

Read More here

 
    Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears  
 
    Noxopharm Updated Corporate Presentation  
 
    Noxopharm Updated Corporate Presentation  
 
    Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears  
 
    Change of Registered Office and Principal Place of Business  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4G and Corporate Governance Statement  
 
    FY21 Corporate Governance Statement and Appendix 4G  
 
    FY23 Board Skills Matrix Summary  
 
    Anti-Bribery and Corruption Policy  
 
    Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results  
 
    Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results  
 
    Cleansing Notice  
 
    Application for quotation of securities - NOX  
 
    Pre-clinical Data Supports a Role for Veyonda in COVID-19  
 
    Pre-clinical Data Supports a Role for Veyonda in COVID-19  
 
    NOXCOVID Program to Expand After Positive Phase 1 Results  
 
    NOXCOVID Program to Expand After Positive Phase 1 Results  
 
    Whistleblower Policy  
 
    Trading Halt  
 
    Trading Halt  
 
    Share Registry  
 
    Research and Clinical Programs  
 
    Noxopharm Presents at Broker Briefing 1 July 2021  
 
    Cleansing Notice  
 
    Application for quotation of securities - NOX  
 
    Noxopharm Presents at the Stockhead V-CON Biotech virtual event  
 
    Presentation at Proactive Investors Life Sciences Webinar 10 August 2021  
 
    Privacy  
 
    Privacy Policy  
 
    Presentation at Proactive Investors Life Sciences Webinar 10 August 2021  
 
    Additional Information on US NCI Collaboration  
 
    NOX and US Govt Peak Cancer Agency Announce Collaboration  
 
    Australian health industry news platform Health Industry Hub reported Noxopharm's confirmation of a survival advantage when Veyonda is added to LuPSMA in an animal study conducted at The University of Queensland.  

Pharmaceutical News: Survival benefit of Noxopharm's Veyonda combination confirmed.

Read More here

 
    Veyonda Survival Advantage in LuPSMA Therapy Confirmed  
 
    Veyonda Survival Advantage in LuPSMA Therapy Confirmed  
 
    Overview  
 
    Noxopharm Constitution - 2019 AGM  
 
    June 2021 Quarterly Activities Report and Appendix 4C  
 
    Share Price Information  
 
    June 2021 Quarterly Activities Report and Appendix 4C  
 
    June 2021 Quarterly Activities Report and Appendix 4C  
 
    Sustainability  
 
    Noxopharm Presents at Broker Briefing 1 July 2021  
 
    BiotechDispatch reported; FDA grants approval for Noxopharm's DARRT-2 cancer study - Biotech  

BiotechDispatch: Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug (IND) approval to the DARRT-2 study.

Read More here

 
    Proactive Investors wrote; Noxopharm Ltd set for busy six months ahead with strong news flow expected from drug pipeline  

Proactive: Noxopharm Ltd (ASX:NOX) is set for a very busy six months ahead with news flow expected from its Veyonda® immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells. 

Read More here

 
    DARRT-2 Study Receives IND Approval from FDA  
 
    Noxopharm Presents at the Stockhead V-CON Biotech virtual event  
 
    Noxopharm Secures Key European Patent Allowance for Veyonda  
 
    Noxopharm Corporate Presentation  
 
    Noxopharm Corporate Presentation  
 
    Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy  
 
    Cleansing Notice  
 
    Application for quotation of securities - NOX  
 
    Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides  
 
    Noxopharm June 2021 Newsletter Released  
 
    DARRT-2 Study Update and Clarification  
 
    The Noxopharm Newsletter June 2021  
 
    Noxopharm Set to Benefit From Novartis ASCO Data  
 
    Becoming a substantial holder  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - BP  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Appendix 3G  
 
    Noxopharm Extraordinary General Meeting Results  
 
    New Independent Trial Data Supports Potential of Veyonda  
 
    Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy  
 
    Noxopharm Presents to Share Café Hidden Gems Webinar  
 
    Noxopharm to Present to Share Cafe Hidden Gems Webinar  
 
    NOXCOVID Trial Achieves Full Enrolment  
 
    Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential  

Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential. CEO Dr. Graham Kelly discusses the history of Veyonda, details of the NOXCOVID study and next steps with Jenni Spinner, editor.

Read More here

 
    Cleansing Notice  
 
    Appendix 2A  
 
    Veyonda FDA Approved Trial to Commence  
 
    Securities Trading Policy  
 
    Gobal Pharma Update: Noxopharm’s Veyonda Prevents Cytokine Storm In Covid-19 Trial  

Global Pharma Update reported, "Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients"

Read More here

 
    Cleansing Notice  
 
    Appendix 2A  
 
    Change of Director's Interest Notice - BP  
 
    Lapsing of Unlisted Options  
 
    Proactive Investors: Noxopharm's CEP-1 trial in peer-reviewed journal Current Therapeutic Research  

Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"

Read more here.

 
    Publications Positive Review of Veyonda in Chemotherapy  
 
    Notice of General Meeting/Proxy Form  
 
    CEO Dr Graham Kelly speaks with The Inside Network  
 
    BioSpace: Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm  

Biospace reported, Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19.

Read More here

 
    Barron: Clinical Data Shows Noxopharm's Veyonda(R) May Prevent Cytokine Storm  

Barron's reported: "Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19"

Read more here.

 
    CEO Dr Graham Kelly speaks with The Inside Network  
 
    March Quarterly Activities Report and Appendix 4C  
 
    March Quarterly Activities Report and Appendix 4C  
 
    Interview with Proactive Investors: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial  
 
    TrialSiteNews: Read more about Noxopharm's patent application for a septic shock treatment here  

TrialSiteNews reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

 
    Veyonda Showing Potential to Prevent Cytokine Storm  
 
    Pause in Trading  
 
    SBS News: Hope for men with advanced prostate cancer after Australian treatment trials  

SBS online reported, "Hope for men with advanced prostate cancer after Australian treatment trials".

Read more here.

 
    The Wall Street Journal: Digital news site posted the announcement  

THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"

Read more here.

 
    The American Pharmaceutical Review: Reported on Noxopharm filing a patent application for Veyonda for septic shock  

American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

 
    Cleansing Notice  
 
    Appendix 2A  
 
    Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021  
 
    Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021  
 
    Proactive Investors: A multi-media business news platform reported the following on Noxopharm Limited  

proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."

Read more here.

 
    Health Industry Hub: Australian pharmaceutical news site, Health Industry Hub, posted; Noxopharm patent to protect use of drug candidate beyond cancer into septic shock  

Noxopharm patent to protect use of drug candidate beyond cancer into septic shock.

Read more here.

 
    Veyonda Patent Lodged for Major Septic Shock Opportunity  
 
    Corporate Presentation for Switzer Virtual Investor Day  
 
    Corporate Presentation for Switzer Virtual Investor Day  
 
    The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer  
 
    The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer  
 
    Health Industry Hub: Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment  

Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"

Read more here.

 
    Noxopharm IONIC Immuno-Oncology Trial Commences  
 
    Noxopharm Limited - ASX Small & Mid Cap Conference 2021  
 
    Noxopharm Presents to the ASX Small & Mid Cap Conference March 2021  
 
    Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021  
 
    Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021  

Noxopharm with Proactive at the ASX Small and Mid-Cap Conference (proactiveinvestors.com.au)

 
    ASX Small-Mid Cap Conference Corporate Presentation  
 
    ASX Small-Mid Cap Conference Corporate Presentation  
 
    NOXCOVID Trial Advances to Final Stage  
 
    Noxopharm Presents to H.C. Wainwright Global Conference  
 
    Noxopharm Presents to H.C. Wainwright Global Conference  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate  
 
    Proposed issue of Securities - NOX  
 
    Lapsing of Unlisted Options and Shortfall Shares  
 
    Change of Director's Interest Notice - PM  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - GK  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Company Announcement Regarding Appendix 3Y Disclosures  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - GK  
 
    BioWorld: Conference data for Feb. 11, 2021: ASCO GU  

In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.

Read more here.

 
    Noxopharm Updated Corporate Presentation February-March 2021  
 
    Noxopharm Updated Corporate Presentation February-March 2021  
 
    Option Underwriting Agreement to Secure Funds  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Noxopharm CEO Letter to Shareholders February 2021  
 
    Appendix 4D and Half Year Financial Report  
 
    Appendix 4D and Half Year Financial Report  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    LuPIN Survival Outcome Confirmed by Conference Presentation  
 
    Bloomberg: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference  

Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.

Read more here.

 
    Noxopharm study finds its drug improves prostate cancer survival rates  
 
    Noxopharm study finds its drug improves prostate cancer survival rates  
 
    PharmaVoice: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference  

PharmaVOICE.com, the digital resource for life-sciences executives and other healthcare-service related professionals provided the following.

Read more here.

 
    BioSpace: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference  

Digital hub for Life Science industry news, BioSpace, shared the following release after the ASCO GU Cancers Symposium.

Read more here.

 
    Biotech Dispatch: Noxopharm uses global conference to update on Veyonda combination study  

Biotech Dispatch, a news site dedicated to the breaking news and commentary about the Australian biotechnology and Life Sciences sector reported.

Read more here.

 
    Major Survival Benefit in Prostate Cancer Patients Announced  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Noxopharm (ASX:NOX) - Hidden Gems Webinar Presentation - ShareCafe  
 
    Noxopharm To Present to ShareCafe Hidden Gems Webinar  
 
    Noxopharm To Present to ShareCafe Hidden Gems Webinar  
 
    Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C  
 
    Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Health Industry Hub: Australia’s Noxopharm advances NOXCOVID study  

Australian pharmaceutical industry news site, Health Industry Hub also reports, "Australia's Noxopharm advances NOXCOVID study".

Read more here. 

 
    Noxopharm (ASX:NOX) Advances Study For NOXCOVID  

The West Australian Newspaper reported today on Noxopharm's announcement that its European NOXCOVID trial in COVID-19 patients has been cleared to administer to the fifth and final dosage cohort.

Read more here. 

 
    Business News Australia: Noxopharm COVID-19 treatment trial advances to the final stage  

Business News Australia reported that Noxopharm's COVID-19 treatment trial advances to the final stage.

Read more here.

 
    The Market Herald: Noxopharm (ASX:NOX) cleared to up dosage in COVID study  

The Market Herald reported, "Noxopharm (ASX:NOX) cleared to up dosage in COVID study

Read more here.

 
    Online News: Noxopharm COVID-19 treatment trial advances to the final stage  

Australian Online News business news section reported on Noxopharm's COVID-19 treatment trial:

Read more here. 

 
    NOXCOVID Study Advances  
 
    Unlisted Options Expiring 28 February 2021  
 
    Noxopharm Shareholder Update 2021  
 
    Reach Markets: How Noxopharm spent a pandemic-plagued 2020 leading the fight against cancer  

Australian Financial Services company, Reach Markets, interviewed CEO Dr Graham Kelly for their December Newsletter.

To read more click here;

 
    Federal Government Approved Future Overseas R&D Expenditure  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Change of Director's Interest Notice - BP  
 
    Change of Director's Interest Notice - FB  
 
    Appendix 3G  
 
    Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.  
 
    Noxopharm (ASX:NOX) announces first COVID-19 patient treated in Veyonda study  
 
    Switzer Small & Micro Cap Virtual Investor Day 2020  
 
    December Investor Webinar Recording  
 
    Change in substantial holding  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.  
 
    Noxopharm Corporate Presentation December Investor Webinar  
 
    Noxopharm Corporate Presentation December Investor Webinar  
 
    The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly  
 
    Pre-Clinical Breakthrough Discovery Set to Expand Pipeline  
 
    Pharmaceutical News - Noxopharm secures $23 mil to fund cancer trials (healthindustryhub.com.au)  

Health Industry Hub, Australian digital news site for Pharma, MedTech and Biotech industries and key industry stakeholders, informed;

Click here to read further

 
    Noxopharm December Investor Webinar Details  
 
    Biotech Finances: Independent Discovery Validates Noxopharm's DARRT Cancer Therapy  

French language news site dedicated to health technologies, Biotech Finances, covered the recent announcement;

Click here to read more

 
    PharmaVoice.com: Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy  

A resource for life-sciences executives and other healthcare-service related professionals" posted the following News Release;

Click here to read more

 
    BioSpace: Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy  

BioSpace, the Life Science industry digital news and information source reported,

Click here to read more

 
    Cleansing Statement  
 
    Proposed issue of Securities - NOX  
 
    Noxopharm Completes A$23m Placement to Fund Clinical Studies  
 
    Switzer Small & Micro Cap Virtual Investor Day 2020  
 
    Australian Financial Review: Noxopharm targets $20m deal for clinical studies  

Australian Financial Review's Street Talk wrote, Noxopharm Targets A$20M Deal for Clinical Studies

Click here to read more

 
    Appendix 2A  
 
    Trading Halt  
 
    Change of Director's Interest Notice - PM  
 
    Lapsing of Unlisted Options  
 
    Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma  
 
    Change of Director's Interest Notice - GK  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    Appendix 3G  
 
    Further Independent Support for Veyonda as a Major I-O Drug  
 
    Noxopharm Annual General Meeting Results  
 
    Noxopharm 2020 AGM Corporate Update  
 
    Noxopharm 2020 AGM Corporate Update  
 
    2020 AGM Chairman's Address  
 
    TrialSite News: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”

Click here to read more

 
    CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV  
 
    The Market Herald: Major breakthrough validates Noxopharm’s (ASX:NOX) cancer therapy  

Australian stock market digital news site, The Market Herald, reported "Major breakthrough validates Noxopharm's(ASX:NOX) cancer therapy", following the November 13, 2020 ASX announcement regarding independent Weill Cornell Medical College research.

Click here to read more

 
    Investing.com(AU): BRIEF-Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product  

Investing.com(AU) mentioned in a Brief: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

 
    Yahoo!Finance: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more

 
    Independent Discovery Validates DARRT Cancer Therapy  
 
    MarketWatch: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content


 
    TD Ameritrade: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product  

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

 
    BioSpace: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more

 
    BioWorld: Other news to note for Nov. 12, 2020  

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more

 
    FirstWord Pharma: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more

 
    PharmaVoice: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more

 
    BiotechDispatch: Noxopharm announces Veyonda to be studied in new immunotherapy trial  

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported

 
    Veyonda To Be Tested In Combination With Opdivo In Trial  
 
    Dedicated Septic Shock Company Established  
 
    NOXCOVID Study Cleared To Expand  
 
    2020 Annual General Meeting Reminder  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    First Two Cohorts Enrolled in NOXCOVID Study  
 
    Noxopharm September 2020 Quarterly Activities Report & Appendix 4C  
 
    Cover Letter and Proxy Form - Annual General Meeting  
 
    Notice of Annual General Meeting and Proxy Form  
 
    "How Do You Approach a Black Swan?" - article from Australasian Biotechnology Journal Volume 30 October 2020  
 
    LuPIN Study Achieves Final Patient Treatment  
 
    Noxopharm CMO discusses first patient treated in NOXCOVID trial  
 
    Pharmaceutical Business Review: Noxopharm announces first Covid-19 patient treated in Veyonda study  

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more

 
    Noxopharm CMO Discusses the NOXCOVID trial  
 
    Unlisted Options Expiring 27 November 2020  
 
    Cleansing Notice  
 
    Appendix 2A  
 
    PharmaVOICE: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

 
    Bloomberg: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

Bloomberg reported on Noxopharm's October 2, 2020 ASX announcement Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

 
    BioWorld: In the clinic for Oct. 8, 2020  

BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

 
    BioSpace: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

BioSpace, a US Life Sciences industry digital hub reported," Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

 
    Noxopharm Loan Terms Amended to Benefit Company  
 
    First COVID-19 Patient Treated in Veyonda Study  
 
    Noxopharm Corporate Presentation September 2020  
 
    Noxopharm Corporate Presentation September 2020  
 
    Noxopharm Appoints US Corporate Advisory and Consulting Firm  
 
    Notification of Date of 2020 Annual General Meeting  
 
    Annual Report to shareholders  
 
    Annual Report to shareholders  
 
    Appendix 4G and Corporate Governance Statement  
 
    Noxopharm Appoints New Chair  
 
    Global CRO To Execute DARRT-2 Prostate Cancer Study  
 
    Veyonda COVID-19 Study Approved For Immediate Start  
 
    Final Director's Interest Notice - ID  
 
    Appendix 4E and Audited Financial Statements FY2020  
 
    Appendix 4E and Audited Financial Statements FY2020  
 
    Appendix 4G and Corporate Governance Statement  
 
    Noxopharm Announces Board Changes  
 
    BioWorld: Other news to note for Aug. 18, 2020  

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.

 
    Pitt Street Research Noxopharm CEO interview August 2020  
 
    Meet the CEO's" Virtual Event July 8, 2020 Recording  
 
    Pitt Street Research Noxopharm CEO interview August 2020  
 
    Clinical Research News: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

 
    FirstWord Pharma: Noxopharm Announces New Research Showing Veyonda Cancer Survival Rates  

Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda®'s trials in late -stage prostate cancer.

Click here to read more.

 
    PharmaVOICE: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

 
    BioSpace: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.

Click here to read more.

 
    Appendix 2A - Shares  
 
    Cleansing Notice  
 
    Appendix 2A - Underwriter Options  
 
    Results of Meeting  
 
    Noxopharm August 2020 EGM Corporate Presentation  
 
    Noxopharm August 2020 EGM Corporate Presentation  
 
    Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer  
 
    Peer-Reviewed Publication Strengthens Case For Veyonda  
 
    Noxopharm Extraordinary General Meeting Reminder  
 
    Clinical Research News: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’  

US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.

Click here to read more.

 
    Noxopharm 2020 June quarter Appendix 4C & Activities Report  
 
    Noxopharm June 2020 Quarterly Activities Report & Appendix 4C  
 
    Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists  
 
    Change of Director's Interest Notice - FB  
 
    Notice of Contravention of Listing Rule 10.11  
 
    BioWorld: Other news to note for July 23, 2020  

BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate, and sphingosine-1-phosphate inhibitor, Veyonda, activate cancer-fighting immune cells and then enable their entry into microtumors. Noxopharm said other preclinical and clinical data, together with the new research data, leads the company to believe it is close to claiming the first drug capable of converting tumors from cold to hot across multiple cancer types in a well-tolerated way"

Click here to read more.

 
    BioSpace: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’  

US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.

Click here to read more.

 
    Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours  
 
    FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours  
 
    Noxopharm Discusses Converting Cold to Hot Cancer Tumours  
 
    Receipt of cash payment for collateral shares  
 
    Data Shows Idronoxil Holds Key to Problem of COLD Cancers  
 
    Noxopharm July 2020 Newsletter Released  
 
    Noxopharm July 2020 Newsletter Released  
 
    Letter to Shareholders - Extraordinary General Meeting  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording  
 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Ceasing to be a substantial holder  
 
    Clinical Research News: New Data Shed Light On T-Cell Response To COVID-19, Other News  

US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.

Click here to read more.

 
    Genetic Engineering and Biotechnology News (GEN): Noxopharm – Veyonda®  

Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19  treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated with COVID-19.

Click here to read more.

 
    Change of Director's Interest Notice - FB  
 
    CenterWatch: COVID-19 Drug Research Roundup  

CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe.

Click here to read more.

 
    Pharmaceutical Business Review (UK): Noxopharm begins NOXCOVID-1 trial of Veyonda in Europe  

In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe.

Click here to read more.

 
    Change in substantial holding - amended  
 
    Change in substantial holding  
 
    Noxopharm Chair Letter to Shareholders  
 
    COVID-19 Trial Program to Commence in Europe  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - BP  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - GK  
 
    Appendix 2A - shares  
 
    Appendix 2A - options  
 
    Pro-rata Non-Renounceable Rights Issue Fully Allocated  
 
    Rights Issue Close Date  
 
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3G Adjustment to Option Exercise Prices  
 
    ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer  
 
    Listing Rule 6.22.2 Adjustment to Option Exercise Prices  
 
    Proposed issue of Securities - NOX  
 
    Entitlement Offer Prospectus May/June 2020  
 
    Despatch of Pro Rata Entitlement Offer Documents  
 
    FDA allows Veyonda Pre-IND Submission for COVID-19  
 
    Noxopharm ASCO Abstracts Live  
 
    Appendix 2A  
 
    Entitlement Offer Prospectus  
 
    Entitlement Offer - Letter to Optionholders  
 
    Entitlement Offer - Letter to Ineligible Shareholders  
 
    Entitlement Offer - Letter to Eligible Shareholders  
 
    Proposed issue of Securities - NOX  
 
    $7.9 Million Fully Underwritten Entitlement Offer Announced  
 
    Initial Director's Interest Notice - FB  
 
    Appointment of New Board Member  
 
    Trading Halt  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Noxopharm March 2020 Quarterly Report & Appendix 4C  
 
    Noxopharm March 2020 Quarterly Report & Appendix 4C  
 
    Abscopal Responses Achieved in Prostate Cancer  
 
    Pipeline Expands With Potential New Brain Cancer Treatment  
 
    BioWorld: Australia’s biotech sector tests multiple agents to fight COVID-19  

US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19.

Click here to read more.

 
    Approval to be sought for COVID-19 Clinical Study in U.S.  
 
    Receipt of cash payment for collateral shares  
 
    Noxopharm trial data to be presented at ASCO 2020  
 
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
    Noxopharm Investigating Potential COVID-19 Treatment  
 
    Noxopharm Virtual Roadshow Corporate Presentation  
 
    Noxopharm Virtual Roadshow Corporate Presentation  
 
    Initial Director's Interest Notice  
 
    Appointment of New Board Member  
 
    Veyonda® Mode of Action  
 
    Veyonda Awarded First Allowed Patent Application  
 
    Veyonda Clinical Program Update and Guidance  
 
    Drug Delivery and Development: EXECUTIVE INTERVIEW - Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer  
 
    LuPIN Prostate Cancer Trial Fully Recruited  
 
    Noxopharm Corporate Presentation February 2020  
 
    Noxopharm Corporate Presentation February 2020  
 
    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
 
    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
 
    Half Year Accounts and Chairman Letter  
 
    Half Year Accounts and Chairman Letter  
 
    Section 708 Certificate  
 
    Appendix 2A  
 
    FDA grants IND approval to Veyonda  
 
    Termination of Convertible Loan  
 
    Section 708 Certificate  
 
    Appendix 2A  
 
    Noxopharm Alliance With GenesisCare  
 
    Proposed issue of Securities - NOX  
 
    $8.1M Financing & Re-Set of Capital Structure  
 
    Pronounced survival benefit in LuPIN interim trial data  
 
    Trading Halt  
 
    LuPIN interim trial data to be presented at ASCO GU 2020  
 
    Lapsing of Unlisted Options  
 
    Noxopharm December 2019 Quarterly Activities Report & Appendix 4C  
 
    Noxopharm Non-Deal Roadshow Presentation  
 
    Noxopharm Non-Deal Roadshow Presentation  
 
    Noxopharm (ASX:NOX) Veyonda for prostate cancer treatment  
 
    Noxopharm DARRT Animation  
 
    DARRT-1 Clinical Results December 2019  
 
    Appendix 3B  
 
    Listing of Nyrada Inc. spin-off on ASX  
 
    Becoming a substantial holder for NYR  
 
    Noxopharm Corporate Presentation  
 
    Veyonda® - Boosting the effectiveness of radiotherapy  
 
    Ceasing to be a substantial holder  
 
    Change of Director's Interest Notice - GK  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    DARRT-1 Clinical Data Webinar  
 
    DARRT-1 Clinical Data Webinar  
 
    Nyrada IPO Offer Fully Subscribed  
 
    Investor FAQs  
 
    Unlisted Options Expiring 18 January 2020  
 
    Lodgement of Nyrada Inc Supplementary Prospectus  
 
    NOXOPHARM DARRT-1 interview Dec 2, 2019  
 
    Nyrada Inc Initial Public Offering Opens  
 
    Section 708 Certificate - Notes  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    AU$2.4m Increase to Funding Agreement  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOXOPHARM DARRT-1 Interview Dec 2, 2019  
 
    Positive DARRT-1 Data in Late-Stage Prostate Cancer  
 
    Trading Halt  
 
    Lodgement of Nyrada Inc Prospectus - Initial Public Offering  
 
    Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive  
 
    Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive  
 
    NOX 2019 AGM webcast  
 
    Constitution  
 
    Results of Meeting  
 
    Noxopharm 2019 AGM Corporate Presentations  
 
    Noxopharm 2019 AGM Corporate Presentations  
 
    LuPIN Data Being Presented To Conference  
 
    DARRT-1 Interim Data Presented To Conference  
 
    DARRT-1 Interim Data Presented To Conference  
 
    LuPIN Data Being Presented To Conference  
 
    Appointment of Chief Commercial Officer  
 
    Noxopharm October 2019 Newsletter  
 
    Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019  
 
    Dr Graham Kelly to Assume CEO Role  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
    Durable Anti-Cancer Effect Confirmed in DARRT-1 Study  
 
    Notice of 2019 Annual General Meeting & Proxy Form  
 
    Potential Fundamental Change in Treatment of Brain Cancer  
 
    New Executive Appointments and Board Change  
 
    Final Director's Interest Notice  
 
    Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial  
 
    Noxopharm 2019 Annual General Meeting Details  
 
    Noxopharm 2019 Annual General Meeting Details  
 
    FNN Interview: The LuPIN trial with Veyonda in prostate cancer  
 
    FNN Interview: The LuPIN trial with Veyonda in prostate cancer  
 
    Further Review Shows Major Clinical Benefits from Veyonda  
 
    Further Review Shows Major Clinical Benefits from Veyonda  
 
    Annual Report to Shareholders  
 
    Corporate Governance Statement - Appendix 4G  
 
    Appendix 4G  
 
    Corporate Governance Statement  
 
    Corporate Governance Statement  
 
    Section 708 Certificate  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Annual Report to Shareholders  
 
    Departure of Dr Van Wyk  
 
    Departure of Dr Van Wyk  
 
    BiotechDispatch: Noxopharm Confirms Veyonda Presentation at Two Conferences  

Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch

 
    Veyonda and Radiotherapy Profiled at Key Oncology Meeting  
 
    Results of Meeting  
 
    NOX EGM Chairman's Address and Presentation  
 
    NOX EGM Chairman's Address and Presentation  
 
    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
    Veyonda® Research at Major Oncology Conferences  

Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas

 
    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
    Healthcare Tech Outlook: Veyonda with Radiotherapy Provides Anti-Cancer Treatment  

US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.

 
    Appendix 4E and Audited Financial Statements FY19  
 
    FY 19 Appendix 4E and Audited Financial Statements  
 
    Addendum to Notice of Extraordinary General Meeting  
 
    CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results  
 
    Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment - Further Promising Results  

Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.

 
    More Evidence that Veyonda Enhances RT in Prostate Cancer  
 
    NOX Receives FY19 Federal Government R&D Tax Rebate  
 
    Appendix 3B  
 
    Cleansing Statement  
 
    Pre-Clinical Evidence Confirms Veyonda Abscopal Effect  
 
    Biotech Dispatch: Sydney-based Noxopharm looking to make 'cold' tumours 'hot'  

Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.

 
    Lead Manager Appointed for Proposed Nyrada IPO  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Noxopharm Corporate Update Interview  
 
    Noxopharm (ASX:NOX) 3-year listing anniversary update  
 
    Noxopharm August 2019 Corporate Presentation  
 
    Noxopharm August 2019 Corporate Presentation  
 
    NOX Releases Initial Newsletter for Nyrada Subsidiary  
 
    Appendix 4C - Quarterly Report for the quarter ending June 30, 2019  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    NOX Announces AU$26 Million Funding Facility  
 
    NOX Announces AU$26 Million Funding Facility  
 
    NOX Releases Latest Newsletter  
 
    NOX Releases Latest Newsletter  
 
    Board Changes Ahead of Corporate Growth  
 
    LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019  
 
    LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019  
 
    Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA  
 
    Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.  
 
    Dot Med: New combination therapy established as safe and effective for prostate cancer  
 
    Conference Hears of Positive Interim Data from LuPIN Trial  
 
    Conference Hears of Positive Interim Data from LuPIN Trial  
 
    News Medical: Novel combination therapy shown to be safe and effective for prostate cancer patients  
 
    Radiology Business: A new treatment option for prostate cancer patients  
 
    SNMMI: Press Release—Society of Nuclear Medicine and Molecular Imaging  
 
    UPI: A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows  
 
    Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA  
 
    NOX Subsidiary, Nyrada Inc, Receives R&D Rebate  
 
    Noxopharm Corporate Presentation June 2019  
 
    Noxopharm Corporate Presentation June 2019  
 
    Noxopharm Corporate Presentation June 2019  
 
    DARRT-1 Study Fully Enrolled  
 
    DARRT-1 Study Fully Enrolled  
 
    Linked In Advertisement Communications Manager May, 2019  
 
    Promising Data Leads to Expansion of LuPIN Trial  
 
    Promising Data Leads to Expansion of LuPIN Trial  
 
    LuPIN Trial Demonstrates High Rates of Response  
 
    Drug Discovery News May 2019 : A booster for immuno-oncology drugs  
 
    Switzer Daily: How a biotech company could change cancer treatment  
 
    Change of Director's Interest Notice - GK  
 
    Appendix 3B  
 
    From Academia To Pharma CEO: Challenges And Lessons Learned – Dr Graham Kelly Noxopharm Executive Chairman and Founder  
 
    DARRT Treatment Has Lasting Disease Control at Six Months  
 
    CEO Interview DARRT Program 6-month Interim Results  
 
    Success  
 
    Reference of Cancer Statistics  
 
    Veyonda and Immuno-Oncology Effect Explained  
 
    Appendix 4C - Quarterly  
 
    Change in Noxopharm Limited Board Structure  
 
    Idronoxil Confirmed as New Immuno-Oncology Drug  
 
    Idronoxil Confirmed as New Immuno-Oncology Drug  
 
    Veyonda Chemotherapy Enhancement Program to be Expanded  
 
    Veyonda Chemotherapy Enhancement Program to be Expanded  
 
    Securities to be released from Voluntary Escrow  
 
    Updated Top 20 shareholder List  
 
    Noxopharm Ausbiotech Asia Series March 2019 Presentation  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Becoming a substantial holder  
 
    KZA: Kazia sells stake in Noxopharm  
 
    NOX provides update to Nyrada Note Holders  
 
    New Corporate Presentation Released  
 
    March 2019 Corporate Presentation  
 
    FNN - Shaw & Partners Investor Event 26.2.19  
 
    Noxopharm to expedite Veyonda Clinical Program  
 
    Noxopharm to expedite Veyonda Clinical Program  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Change of Director's Interest Notice - GK  
 
    St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    Chief Medical Officer Discusses DARRT-1 trial interim results  
 
    Veyonda and Radiotherapy Delivers Clinical Benefits  
 
    Veyonda and Radiotherapy Delivers Clinical Benefits  
 
    Appendix 3B  
 
    Appendix 4C - quarterly report for the quarter ended December 31, 2018  
 
    Appendix 4C - quarterly report for the quarter ended December 31, 2018  
 
    Principal Investigator Discusses LuPIN-1 Study  
 
    Change of Director's Interest Notice - GK  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX Receives $3.26M Federal Govt R&D Rebate  
 
    DARRT-1 study advancing on basis of positive clinical data  
 
    DARRT-1 study advancing on basis of positive clinical data  
 
    NOX announces Positive Data from CEP-1 Study of Veyonda  
 
    NOX announces Positive Data from CEP-1 Study of Veyonda  
 
    2018 Annual General Meeting podcast  
 
    Initial Director's Interest Notice  
 
    Results of Meeting  
 
    Appointment of Mr John Moore as Non-Executive Director  
 
    NOX 2018 AGM Presentations  
 
    NOX 2018 AGM Presentations  
 
    NOX 2018 AGM Presentations  
 
    NOX 2018 AGM Information  
 
    Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study  

Poster at COSA Annual Meeting Perth November 2018

 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

Poster at COSA Annual Meeting Perth November 2018

 
    NOX to Present Clinical Data at COSA Annual Meeting  
 
    NOX to Present Clinical Data at COSA Annual Meeting  
 
    Corporate Presentation  
 
    Corporate Presentation  
 
    Appendix 4C - Quarterly report for the quarter ended September 30, 2018  
 
    NOX makes key executive appointment  
 
    NOX makes key executive appointment  
 
    Study of Radiotherapy with NOX66 patients  
 
    Notice of Annual General Meeting & Proxy Form  
 
    Noxopharm Releases Report on Key Progress of Subsidiary  
 
    Noxopharm Releases Report on Key Progress of Subsidiary  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Change of Director's Interest Notice - PM  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Change of Registry Address: Automic P/L - Sydney Office  
 
    Annual Report to shareholders  
 
    Annual Report to shareholders  
 
    Annual Report to shareholders  
 
    Corporate Governance Statement - Appendix 4G  
 
    Corporate Governance Statement - 2018  
 
    NOX Subsidiary Announces Important Drug Discovery  
 
    NOX Subsidiary Announces Important Drug Discovery  
 
    September 2018 Newsletter  
 
    NOX to support expanded LuPIN study  
 
    Appendix 4E and Audited Financial Statements  
 
    Nyrada-Key progress with cholesterol-lowering drug candidate  
 
    Nyrada-Key progress with cholesterol-lowering drug candidate  
 
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
    VEYONDA - Registered Trade Mark for NOX66  
 
    VEYONDA - Registered Trade Mark for NOX66  
 
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
    NOX Corporate Presentation FNN-Shaw&Partners Investor Event  
 
    Change of Director's Interest Notice - GK  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3B  
 
    Interim NOX66 Radiotherapy Clinical Data  
 
    Interim NOX66 Radiotherapy Clinical Data  
 
    Appendix 4C- Quarterly report for the quarter ended June 30, 2018  
 
    Appendix 4C- Quarterly report for the quarter ended June 30, 2018  
 
    Noxopharm June 2018 Open Briefing  
 
    Securities to be released from Escrow  
 
    NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study  

Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

 
    Release of DARRT-1 Preliminary Safety Data  
 
    Release of DARRT-1 Preliminary Safety Data  
 
    Pre-Clinical data confirms Radio-Enhancing potential  
 
    Pre-Clinical data confirms Radio-Enhancing potential  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  
 
    End-of-Study Clinical Data shows benefit of NOX66  
 
    End-of-Study Clinical Data shows benefit of NOX66  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX to present at American Society of Clinical Oncology  
 
    NOX to present at American Society of Clinical Oncology  
 
    Change in substantial holding  
 
    Securities to be released from Voluntary Escrow  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    Results of Meeting  
 
    NOX CEO interview updates the company's current R&D program  
 
    NOX CEO interview updates the company's current R&D program  
 
    Noxopharm CEO Interview Updates the Company's Current Research and Development Program  
 
    NOX CEO interview on near complete NOX66 chemotherapy trial  
 
    NOX CEO interview on near complete NOX66 chemotherapy trial  
 
    Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1  
 
    Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs  
 
    NOX CEO interview on Radiotherapy Clinical Programs  
 
    NOX CEO interview on Radiotherapy Clinical Programs  
 
    Appendix 4C - quarterly  
 
    St Vincent's Hospital study passes first milestone  
 
    St Vincent's Hospital study passes first milestone  
 
    Notice of Extraordinary General Meeting / Proxy Form  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    DARRT-1 Clinical Study commences  
 
    DARRT-1 Clinical Study commences  
 
    NOX Mid-Year Briefings  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX raises $10.8 M to advance clinical program  
 
    NOX raises $10.8 M to advance clinical program  
 
    Trading Halt  
 
    Evidence of Abscopal Responses in Patients  
 
    Evidence of Abscopal Responses in Patients  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    FNN Interview with Noxopharm CEO  
 
    FNN Interview with Noxopharm CEO  
 
    NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results  
 
    NOX Reports NOX66 Clinical Data  
 
    NOX Reports NOX66 Clinical Data  
 
    Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7  
 
    Trading Halt  
 
    Update accompanying Half Year Report  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    NOX closes $4m capital raising for US subsidiary Nyrada Inc  
 
    NOX closes $4m capital raising for US subsidiary Nyrada Inc  
 
    Appendix 4C - quarterly  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Study of Radiotherapy with NOX66 in patients with late-stage Prostate Cancer open for Recruitment in Australia  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX receives FY17 R&D Tax Rebate  
 
    NOX receives FY17 R&D Tax Rebate  
 
    Kazia Therapeutics Ltd and Noxopharm Ltd  
 
    EOY Guidance on 2018 NOX66 Clinical Development Strategy  
 
    EOY Guidance on 2018 NOX66 Clinical Development Strategy  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Appendix 3B  
 
    Change of Registered Office  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX Open Briefing Corporate Presentation  
 
    NOX Open Briefing Corporate Presentation  
 
    NOX Open Briefing Corporate Presentation  
 
    Compassionate use of NOX66 in Patients  
 
    Compassionate use of NOX66 in Patients  
 
    Nyrada Inc Opens Capital Raise - Memorandum Released  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3B  
 
    Webcast of NOX 2017 AGM  
 
    Noxopharm Limited 2017 AGM Webcast, November 27, 2017  
 
    NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model  
 
    Invitation to Open Briefing  
 
    Results of Meeting  
 
    AGM Presentations  
 
    AGM Presentations  
 
    AGM Presentations  
 
    Clarification of Incorrect Information  
 
    Trading Halt  
 
    NOX 2017 AGM Webcast  
 
    Completion of Transfer of Shares to Nyrada Inc  
 
    NOX66 Plus Carboplatin - Phase 1 Signalling Study  
 
    Promising Interim Clinical Data for NOX66  
 
    Promising Interim Clinical Data for NOX66  
 
    Noxopharm video Lupin Study  
 
    Trading Halt  
 
    1st Patient treated in Lupin Study at St Vincent's Hospital  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study  
 
    Idronoxil levels of patients receiving NOX66  
 
    ENOX2 levels of patients receiving NOX66  
 
    NOX making three presentations at COSA  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Results of Meeting  
 
    EGM Presentations  
 
    EGM Presentations  
 
    EGM Presentations  
 
    Noxopharm’s collaboration finds drug to help stroke victims  
 
    UNSW collaboration confirms drug designed for stroke victims  
 
    UNSW collaboration confirms drug designed for stroke victims  
 
    Appendix 4C – Quarterly report for the quarter ended September 30, 2017  
 
    Appendix 4C - quarterly  
 
    AFR Feature : Innovations in Stroke Therapy  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Update - General Meeting Agenda  
 
    Update - General Meeting Agenda  
 
    October 2017 Open Briefing Corporate Presentation  
 
    October 2017 Open Briefing Corporate Presentation  
 
    October 2017 Open Briefing Corporate Presentation  
 
    Invitation to Open Briefing  
 
    Establishment of Nyrada Inc. - Extraordinary General Meeting  
 
    Australian NOX66 - Radiotherapy Study Opens  
 
    Australian NOX66 - Radiotherapy Study Opens  
 
    Establishment of Nyrada Inc.  
 
    Establishment of Nyrada Inc.  
 
    Positive Clinical Outcomes for NOX66 at ESMO Conference  
 
    Positive Clinical Outcomes for NOX66 at ESMO Conference  
 
    Chemosensitization of Carboplatin by NOX66  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice  
 
    NOX CEO Interview explains recent Brain Cancer Announcement  
 
    NOX CEO Interview explains recent Brain Cancer Announcement  
 
    Appendix 4E and Audited Financial Statements  
 
    Appendix 4E and Audited Financial Statements  
 
    Corporate Governance Statement - Appendix 4G  
 
    Corporate Governance Statement  
 
    Important Brain Cancer Findings for NOX66 Program  
 
    Important Brain Cancer Findings for NOX66 Program  
 
    Reinstatement to Official Quotation  
 
    Reinstatement to Official Quotation  
 
    Noxopharm raises $5.5 million to advance clinical program  
 
    Noxopharm raises $5.5 million to advance clinical program  
 
    Suspension from Official Quotation  
 
    Suspension from Official Quotation  
 
    Trading Halt Request  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Trading Halt  
 
    August 2017 Newsletter  
 
    NOX Corporate Presentation ahead of Conference  
 
    Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21  
 
    NOX Corporate Presentation ahead of Conference  
 
    Noxopharm's first 12 months since ASX listing  
 
    New Investor - Shed Connect: Hidden Gems in the Small Caps Space  
 
    Appendix 4C – Quarterly report for the quarter ended June 30, 2017  
 
    Appendix 4C - quarterly  
 
    NOX Research Report prepared by APP Securities  
 
    NOX Research Report prepared by APP Securities  
 
    CEO Interview with FNN - Singapore and HK Roadshow  
 
    CEO Interview with FNN - Singapore and HK Roadshow  
 
    New Corporate Presentation  
 
    New Corporate Presentation  
 
    New Corporate Presentation  
 
    Noxopharm provides update on NOX66 Clinical Trial Program  
 
    Noxopharm provides update on NOX66 Clinical Trial Program  
 
    Shed Connect - The Rub: Noxopharm Prepares for Clinical Trials  
 
    Idronoxil data provides hope to treat secondary brain cancer  
 
    Idronoxil data provides hope to treat secondary brain cancer  
 
    NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment  
 
    NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment  
 
    St Vincent's Hospital Sydney Prostate Cancer Study  
 
    New Corporate Presentation  
 
    New Corporate Presentation  
 
    New Corporate Presentation  
 
    St Vincents Cancer Study to Commence-NOX66 and Radiotherapy  
 
    St Vincents Cancer Study to Commence-NOX66 and Radiotherapy  
 
    NOX makes strategic commitment to treatment of rare cancers  
 
    AFR editorial : Innovations In Cancer Research  
 
    Noxopharm Mid Year Investor Briefings  
 
    Noxopharm Mid Year Investor Briefings  
 
    Market Guidance for Next Six Months  
 
    Market Guidance for Next Six Months  
 
    Appendix 4C – Quarterly report for the quarter ended 31 March 2017  
 
    Appendix 4C - quarterly  
 
    Appendix 4C - quarterly  
 
    Discovery of Idronoxil-C - NOX CEO explains  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    NOX Files Patent Application on 'Smart' Idronoxil  
 
    NOX Files Patent Application on 'Smart' Idronoxil  
 
    Appendix 3B  
 
    Appendix 3B  
 
    NOX and Monash Uni Collaboration Receives Federal Grant  
 
    NOX and Monash Uni Collaboration Receives Federal Grant  
 
    UNSW Newsroom: Working with Noxopharm to prevent traumatic head injury  
 
    Noxopharm and UNSW combine on stroke project  
 
    Noxopharm and UNSW combine on stroke project  
 
    Gold Coast Qld Mid-Year Briefing Details  
 
    Gold Coast Qld Mid-Year Briefing Details  
 
    Notification of Release of Restricted Securities Escrow  
 
    NOX researching rare Abscopal Response  
 
    NOX researching rare Abscopal Response  
 
    ASX The CEO Sessions - ASX Interview  
 
    ASX The CEO Sessions February 2017 Presentation  
 
    Appendix 4D and Half Year Accounts  
 
    NOX Presentation and Interview ASX The CEO Sessions  
 
    ASX CEO Presentation Feb 2017 slides  
 
    ASX CEO Presentation Feb 2017 slides  
 
    Upcoming Events and Presentations  
 
    Upcoming Events and Presentations  
 
    Upcoming Events and Presentations  
 
    Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’  
 
    February 2017 Newsletter  
 
    Change of Principal Place of Business  
 
    Brain Cancer Study Commences  
 
    First NOX66 Clinical Trial to Commence  
 
    Appendix 4C – Quarterly report for the quarter ended 31 December 2016  
 
    Noxopharm CEO to present at ASX The CEO Sessions  
 
    Appointment of New Company Secretary  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - GK  
 
    Market Capitalisation - further update  
 
    Appendix 3B  
 
    Market Capitalisation Update  
 
    Results of Meeting  
 
    Breakthrough in Delivering Idronoxil into Brain  
 
    Breakthrough in Delivering Idronoxil into Brain  
 
    Corporate Presentation Updated  
 
    Corporate Presentation Updated  
 
    November 2016 Corporate Presentation  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    November 2016 Corporate Presentation  
 
    Medical Advisors Appointed for Extensive Clinical Program  
 
    Medical Advisors Appointed for Extensive Clinical Program  
 
    Independent Investment Research Report November 2016  
 
    Change in substantial holding DH  
 
    Appendix 4C – Quarterly report for the quarter ended 30 September 2016  
 
    Appendix 4C - quarterly  
 
    Noxopharm 2016 AGM Sydney Briefing  
 
    Annual Report to shareholders  
 
    Notice of 2016 AGM and 2016 Annual Report  
 
    Corporate Presentation  
 
    Corporate Presentation  
 
    Corporate Presentation  
 
    Annual Report 2016  
 
    Appendix 4G  
 
    Amendment to Preliminary Final Report  
 
    APP Securities Company Research Report September 2016  
 
    Corporate Presentation for Roadshow  
 
    Preliminary Final Report  
 
    Change in substantial holding  
 
    Change in substantial holding DH  
 
    Noxopharm to Initiate Radiotherapy Clinical Studies  
 
    Change of Director's Interest Notice - GK  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice - PM  
 
    Initial Director's Interest Notice - ID  
 
    Initial Director's Interest Notice - GK  
 
    Noxopharm Newsletter  
 
    Noxopharm Limited commences trading on ASX  
 
    Performance Share Terms  
 
    Option Terms  
 
    Restricted Securities and Capital Structure  
 
    Securities Trading Policy  
 
    Financial Accounts  
 
    Constitution  
 
    ASX Market Release - Admission to Official List  
 
    Appendix 1A & Information Form and Checklist  
 
    Top 20 Holders  
 
    Distribution Schedule  
 
    Company's Admission Disclosures  
 
    ASX Market Release - Pre-Quotation Disclosure  
 
    Prospectus  
 
    ASX Notice - Admission and Commencement of Quotation  
 
    Noxopharm Limited Closes Oversubscribed IPO  
 
    Prospectus  
 
    Noxopharm Press Release  
 
    NOX Prospectus 24 June 2016  
 
    NOX Prospectus For Submission 6 June  
 
    Noxopharm Corporate Governance Charters and Policies  
 
    Investor Roadshow Presentation  
 
    Our Approach  
 
    Chart  
 
    Financial Report  
 
    Thank You  
 
    Top 20 Shareholders  
 
    Share Price Information